Table 1 Baseline characteristics (at time of transplantation) and clinical information
From: Circulating cell-free nucleosomes as biomarker for kidney transplant rejection: a pilot study
Study group (n = 20) | ||
|---|---|---|
Age, y | 54 (21–76) | |
Male/Female | 30 (75%)/10 (25%) | |
Etnicity | ||
Caucasian | 33 (82.5%) | |
African | 4 (10%) | |
Asian | 3 (7.5%) | |
Cause of end-stage renal disease | ||
Diabetes mellitus | 10 (25%) | |
Hypertension | 7 (17.5%) | |
IgA nephropathy | 4 (10%) | |
Polycystic kidney disease | 6 (15%) | |
Obstructive nephropathy | 4 (10%) | |
Unknown | 5 (12.5%) | |
Other | 4 (10%) | |
Renal replacement | ||
Preemptive/ non-preemptive | 18 (45%)/22 (55%) | |
No. Kidney transplantation | ||
First | 39 (97.5%) | |
Second | 1 (2.5%) | |
Living donor/deceased donor | 40 (100%)/0 (0%) | |
Immunosuppressive therapy | ||
Belatacept based | 20 (50%) | |
Tacrolimus based | 20 (50%) | |
Biopsy-proven acute rejection (BPAR) | 11 (27.5%) | |
Time to first BPAR (within the first 6 months after transplantation), days | 56 (3–152) | |